NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working.
 |
 |
Update to previous Blog.
As reported by Matt Robinson’s Prescribing adviser blog, Zoledronic acid (AclastaR) has been approved in Europe for the treatment of osteoporosis in post-menopausal women at increased risk of fracture. The summary of product characteristics has been updated to reflect this license extension. Prescribers should consider the issues highlighted in the earlier blog article on this product, in the So what? and Action sections.